Default company panoramic image
B274c421 d3d1 4605 8baa e2568dc5266d

Complexa, Inc.

Complexa is raising a $7-10MM series B open to angel investors, to fund data requested by a pharma needed for an exit/partnership in 18 mos.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded August 2007
  • Employees 5
  • Website

Company Summary

Complexa, Inc is a platform anti-inflammatory company utilizing endogenous mediators that signal the body' s main anti-inflammatory pathways. The company’s lead compound is scheduled to enter the clinic in 3Q13 to treat a form of kidney disease. Comparables (e.g.: Reata) have partnered with similar phase data with collective deal values of nearly $1B. Complexa is raising funds for studies requested by a partner needed to exit


  • Default avatar
    Joshua M Tarnoff
    Pres and CEO, Board Director

    Mr. Tarnoff joined the company in 2011 and brings nearly 30 years of pharmaceutical experience. He has built and led businesses within large pharma and biotechnology as well as early stage start-ups. His most recent roles include CEO of JDP Therapeutics, CEO of Houston Pharma (and its subsidiary Potomac Pharma), and CCO at ViroPharma. He is currently a board member of several early stage healthcare companies.

  • Default avatar
    Hank Safferstein
    Board Director

    Dr. Safferstein is CEOat Cognition Therapeutics. He was VP of BD at Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products. Prior to joining Omrix, he was Executive Vice President, Corporate Development for TransPharma Medical, a privately-held medical device company. From 2001 to 2005, Dr. Safferstein was Vice President, Business Development for Acorda Therapeutics

  • Default avatar
    Joseph Reiser
    Board Chairman

    Dr Reiser has more than 32 years of pharmaceutical and biotech experience. He served as President, Chief Executive Officer and on the Board of CureDM Inc and was President and Chief Executive Officer and board member of Locus Pharmaceuticals, served as President, Chief Executive Officer board member at Cytogen ,Corporate Vice President, GM, and member of the Board of Directors for Berlex Laboratories, Inc

  • Default avatar
    Peter Grebow, PhD
    Board Director

    Dr. Grebow held several key positions with Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, including Executive Vice President, Cephalon Ventures, Executive Vice President, Technical Operations, Senior Vice President, Worldwide Business Development and Senior Vice President, Drug Development. Prior to joining Cephalon, Dr. Grebow was the VP, Drug Development for Rorer Central Research, a division of RPR Pharmaceuticals Inc.

  • Default avatar
    J Carter Meyer
    Board Director

    He has been the Chief Executive Officer of Scientific Health Development (SHD) since its formation in February 2006, and is a General Partner of its most recent fund. SHD is an investment fund focused on earlier stage life science companies and is located in Dallas, Texas. Prior to joining SHD, he was an attorney in private practice for over 12 years, most recently with Vinson & Elkins L.L.P. Mr. Meyer has a B.B.A. in finance.

  • Default avatar
    Wistar Morris
    Board Director

    Mr. Morris is Senior Investment Consultant to Pennsylvania Trust. He retired from Boenning & Scattergood, as a Dir and Invest Advisor for 20 years. Mr. Morris founded the Morris Investment Management Company, and has been on the boards of 20 companies.
    He is trustee to The Academy of Natural Science, Lankenau Medical Ctr, Lankenau Inst of Medical Research, the Mt Desert Island Biological Laboratory, and the Wistar Inst.

  • Default avatar
    Diane Jorkasky, MD
    Chief Medical Officer

    Dr. Jorkasky is a highly regarded medical scientist and researcher in the pharmaceutical industry. Her experience includes positions as Head of Development and Chief Medical Officer at Endo Pharmaceuticals and Vice President of Global Clinical Research Operations. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology has published over 100 peer review articles.

Previous Investors

  • Default avatar
    Scientific Health Development, Wistar Morris Foundation
    Default avatar
    PLSG, Innovation Works (a Ben Franklin Company), UpStart